Organon & Co.
OGN
Rank in Stocks
#4361
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Share Price
$13.75
Market Cap
$3.61B
Change (1 day)
-0.11%
Change (1 year)
48.11%
Country
US
Trade Organon & Co. (OGN)
Category
Healthcare
Earnings for Organon & Co. (OGN)
Earnings in Jun 2026 TTM: $491.00M
According to Organon & Co. latest financial reports the company's current earnings are $491.00M. In 2024 the company made an earning of $807.00M, an increase over its 2023 earnings that were of $673.00M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Organon & Co. from 2017 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $491.00M | 15.53% |
| 2025 | $425.00M | -47.34% |
| 2024 | $807.00M | 19.91% |
| 2023 | $673.00M | -40.02% |
| 2022 | $1.12B | -26.62% |
| 2021 | $1.53B | -44.44% |
| 2020 | $2.75B | -25.54% |
| 2019 | $3.70B | 35.43% |
| 2018 | $2.73B | -11.94% |
| 2017 | $3.10B | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $33.60B | 6,742.28% |
US
|
|
| $17.74B | 3,512.42% |
US
|
|
| $8.70B | 1,671.69% |
US
|
|
| $5.95B | 1,111.41% |
US
|
|
| $21.39B | 4,256.07% |
CH
|
